1990
- Challenge Bioproducts Co., Ltd. began in Touliu.
- The first factory was built in Touliu Industrial Park.
- Office and R&D laboratory built in Taichung.
1998
- CBC's new factory and laboratory built in Touliu.
2001
- CBC was awarded a R.O.C. (Taiwan) patent on the production
technology of Genipin.
- In order to help more 3rd degree patients in the world, CBC
signed Supply Agreement and Technology Transfer agreements with
Mediwound
Ltd. for the pineapple enzyme mixture Bromelain SP.
2003
- CBC was awarded an USA patent on the application of Genipin on
the biomedical engineering field.
- CBC was awarded an European patent on the application of
Genipin on the biomedical engineering field.
- CBC was awarded a Taiwan patent on the application of Genipin
on the biomedical engineering field.
- CBC was awarded a P.R.C. (Mainland China) patent on the
application of Genipin on the biomedical engineering field.
2004
- Chappion Biotechnology Co., Ltd. was established to focus on the
R&D and production of high-tech biomedical and health
food ingredients.
- President CK Lin was awarded the 5th outstanding
alumni of the Engineering School of National Tsing-Hua
University of Taiwan.
2005
- CBC was awarded a Canadian patent on the application of
Genipin on the biomedical engineering field.
2006
- CBC was awarded a Taiwan patent on the application of Genipin
on oil body.
2008
- The first plant of Chappion Biotechnology Co., Ltd. was
established in Touliu Industrial Park, Taiwan.
- Challenge Bioproducts
Co., Ltd. and Chappion Biotechnology Co., Ltd.
were both awarded
ISO 22000 and HACCP certification, by Swiss Certification.
2009
-
MediWound Ltd. (Israel) achieved promising
Phase III trial results on its 3rd degree burn treatment product
in the EU, while the US FDA Phase III trials are underway.
CBC, as the sole supplier of Bromelain SP, expects the
project to revolutionize treatments for 3rd degree burn
patients.
2010
- Manufacturing facilities and hardwares for the production of API intermediate (Bromelain SP) were upgraded, along with an upgraded quality system suitable for Bromelain SP.
2011
- Renewal of ISO 22000 and HACCP certification by
UKAS (United Kingdom Accreditation Service)
via SGS.
- Challenge Bioproducts & Chappion Biotechnology facilities were audited by
Teva Pharmaceuticals Europe (Global Compliance Group), and obtained
EU GMP suitability declaration as a manufacturer of API intermediate (Bromelain SP).
2012
- President CK Lin was invited to the Taiwan-Israel Biotechnology Forum with two Israeli Nobel Laureates at NTHU, Taiwan.
| President CK Lin |
President Shen |
Prof. Ciechanover |
Prof. Yonath |
Ms. Halperin |
Prof. Andrew Wang |
ChallengeBio
ChappionBio |
ApexBiotech
Corp. Taiwan |
Technion-IIT, Israel
Nobel laureate |
WIS, Israel
Nobel laureate |
Representative of
Israel in Taiwan |
Inst. of Biochem.
Academia Sinica |
2012
- Debrase(Nexobrid) receives marketing approval in Europe by EMA, and becomes "the first medical treatment for removal of eschar from severe burn wounds". It is also the first plant-derived enzymatic drug for eschar removal for burn patients.
2013
- To this date, CBC Genipin has been used by more than 220 research institutes/universities in over 45 countries in the world, and published more than 340 peer-reviewed scientific research literatures. We look forward to the bright future of Genipin as an API.
|
